Jeffrey A. Meckler

Jeffrey A. Meckler has been a member of the board of directors of Travere Therapeutics, Inc. since 2014. He brings extensive biopharmaceutical industry experience to Travere and is currently the chief executive officer at Intec Pharma, Ltd. – a clinical stage biopharmaceutical company focused on developing a proprietary drug delivery solution for key unmet needs. Previously, he served as CEO and a director of Cocrystal Pharma, Inc. a pharmaceutical company focused on the discovery of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Earlier in his career, Mr. Meckler was managing director of the Andra Group, a life sciences consulting firm and acted as a director and interim CEO of Cypress Bioscience Inc. after its acquisition by Royalty Pharma. He has also served as a director of QLT, Inc., ClearFarma USA, Kyalin Bioscience and Alveolus Inc. Mr. Meckler held a series of positions at Pfizer Inc. in manufacturing systems, market research, business development, strategic planning and corporate finance, which included playing a significant role in acquisitions and divestitures. Mr. Meckler is the past president and continues to serve on the board of Children of Bellevue, a non-profit organization focused on advocating and developing pediatric programs at Bellevue Hospital Center. Mr. Meckler holds a B.S. in industrial management and M.S. in industrial administration from Carnegie Mellon University’s Tepper School of Business. In addition, Mr. Meckler received a J.D. from Fordham University School of Law.